742 related articles for article (PubMed ID: 21194578)
1. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
Nauck MA
Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
[TBL] [Abstract][Full Text] [Related]
2. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
3. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
4. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
5. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
6. Differentiating incretin-based therapies for population-based health care.
Calabrese D
Am J Manag Care; 2011 Mar; 17(2 Suppl):S52-8. PubMed ID: 21517657
[TBL] [Abstract][Full Text] [Related]
7. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
9. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Neumiller JJ
Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
[TBL] [Abstract][Full Text] [Related]
11. The role of incretin on diabetes mellitus.
Sanusi H
Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
[TBL] [Abstract][Full Text] [Related]
12. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.
Fonseca VA; Zinman B; Nauck MA; Goldfine AB; Plutzky J
Am J Med; 2010 Jul; 123(7):S2-S10. PubMed ID: 20609666
[TBL] [Abstract][Full Text] [Related]
13. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
15. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
16. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
17. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.
Grossman S
Pharmacotherapy; 2009 Dec; 29(12 Pt 2):25S-32S. PubMed ID: 19947814
[TBL] [Abstract][Full Text] [Related]
18. [Incretin and incretin-based therapies].
Harada N; Inagaki N
Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
[TBL] [Abstract][Full Text] [Related]
19. Incretin based therapies for type 2 diabetes mellitus.
Ghosh S; Collier A; Elhadd T; Malik I
J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
Gilbert MP; Pratley RE
Eur J Intern Med; 2009 Jul; 20 Suppl 2():S309-18. PubMed ID: 19580950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]